Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Arenavirus-based Vector Therapy HB-502 and HB-501 in People with HIV on Suppressive Antiretroviral Treatment

Next Previous
Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Arenavirus-based Vector Therapy HB-502 and HB-501 in People with HIV on Suppressive Antiretroviral Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HB-500 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man
  • Sponsors Gilead Sciences

Most Recent Events

  • 30 Jan 2025 According to a Poolbeg Pharma media release, enrolment completed in this trial with 30 patients enrolled across five sites in the United States.
  • 30 Jan 2025 Status changed from recruiting to active, no longer recruiting, according to a Poolbeg Pharma media release.
  • 02 Jan 2025 According to a Poolbeg Pharma media release, primary completion of the Phase 1b trial of HB-500 in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top